Coherus BioSciences, Inc. has received a fresh $50m investment after completing the sale of a little under 2.5 million shares of newly-issued stock to Junshi Biosciences, the Chinese biotech that earlier this year partnered to drastically reshape Coherus’ biosimilar-orientated strategy.
Junshi has acquired 2,491,988 Coherus shares for US$20.06 per share, a 42% premium to the California-based player’s closing share price on 19 April. Coherus’ share price has yo-yoed in 2021, reaching $21
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?